Compare · MAZE vs MRNA
MAZE vs MRNA
Side-by-side comparison of Maze Therapeutics Inc. (MAZE) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MAZE and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $23.67B, about 14.6x MAZE ($1.62B).
- Over the past year, MAZE is up 72.6% and MRNA is up 82.4% - MRNA leads by 9.8 points.
- MRNA has been more active in the news (10 items in the past 4 weeks vs 4 for MAZE).
- MRNA has more recent analyst coverage (25 ratings vs 7 for MAZE).
- Company
- Maze Therapeutics Inc.
- Moderna Inc.
- Price
- $29.32+3.26%
- $59.73+0.07%
- Market cap
- $1.62B
- $23.67B
- 1M return
- +14.31%
- +0.64%
- 1Y return
- +72.57%
- +82.38%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2018
- News (4w)
- 4
- 10
- Recent ratings
- 7
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MAZE
- President, R&D & CMO Bernstein Harold exercised 14,609 shares at a strike of $10.42 and sold $436,864 worth of shares (14,609 units at $29.90) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Coloma Jason V sold $1,034,253 worth of shares (34,501 units at $29.98) as part of a pre-agreed trading plan (SEC Form 4)
- CSBO Dandekar Atul exercised 7,500 shares at a strike of $10.42 and sold $210,150 worth of shares (7,500 units at $28.02) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Maze Therapeutics Inc.
- Chief Executive Officer Coloma Jason V sold $725,495 worth of shares (27,858 units at $26.04) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 4 filed by Director Spiegelman Daniel K
- SEC Form 4 filed by Director Scheller Richard H
- SEC Form 4 filed by Director Lim Jonathan E
- SEC Form 4 filed by Director Hoppenot Herve
- SEC Form 4 filed by Director Homcy Charles J
Latest MRNA
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester